September 22, 2025
Authored and Edited by Devan K.T. Knapp; Umber Aggarwal; Forrest A. Jones
Under the new bifurcated discretionary denial review process, 35 U.S.C. § 325(d) has most often been cited in support of referral due to the need to correct material error by the Office, rather than as a reason for discretionary denial. However, in TankLogix, LLC v. SitePro, Inc., IPR2025-00761, Paper 10 (PTAB Sept. 3, 2025), USPTO Acting Director Coke Morgan Stewart denied institution under § 325(d).
Before addressing § 325(d), the Director concluded the status of the parallel proceeding “neither favor[ed] nor counsel[ed] against discretionary denial” because of the uncertainty whether a final written decision in the IPR would be issued after the district court trial. IPR2025-00761, Paper 10 at 2. The uncertainty arose because the anticipated date for the final written decision, November 19, 2026, fell between the scheduled trial date of October 26, 2026, and statistical projections indicating that the trial could commence in September 2027.
Moving to § 325(d), the Director determined that the four references asserted in the petition were the same as previously presented to the Office during prosecution—three cited by the examiner, and one cited by the applicant. Critically, Petitioner “merely assert[ed] that the Petition ‘details how the references disclose every element of every claim’”—but “[t]his assertion alone [was] insufficient to demonstrate material error by the Office.” IPR2025-00761, Paper 10 at 2-3.
This denial illustrates that, despite the shift in how § 325(d) is being applied, petitioners must still specifically argue how the USPTO erred in evaluating any relied-on references to overcome denial under § 325(d).
Copyright © 2025 Finnegan, Henderson, Farabow, Garrett & Dunner, LLP.
DISCLAIMER: Although we wish to hear from you, information exchanged in this blog cannot and does not create an attorney-client relationship. Please do not post any information that you consider to be personal or confidential. If you wish for Finnegan, Henderson, Farabow, Garrett & Dunner, LLP to consider representing you, in order to establish an attorney-client relationship you must first enter a written representation agreement with Finnegan. Contact us for additional information. One of our lawyers will be happy to discuss the possibility of representation with you. Additional disclaimer information.
At the PTAB Blog
IPR and PGR Statistics for Final Written Decisions Issued in March and April 2026
May 26, 2026
At the PTAB Blog
May 20, 2026
Conference
19th Annual Forum on Pharma & Biotech Patent Litigation in Europe
May 19-20, 2026
Amsterdam
Due to international data regulations, we’ve updated our privacy policy. Click here to read our privacy policy in full.